Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
While GLP-1 drugs have existed since the early 2000s, semaglutide revealed their potential beyond diabetes, particularly in obesity, where past treatments were often found inadequate
While its pathogenesis remains largely unknown, genetic, hormonal, and microvascular factors have been implicated
Tirzepatide is administered once weekly via subcutaneous injection, with doses ranging from 2.5 mg to 15 mg depending on therapeutic goals and tolerability
Quick Answer: Tirzepatide burns fat primarily by reducing appetite and caloric intake through dual GIP and GLP-1 receptor activation, creating an energy deficit that promotes fat mobilization and oxidation
US$ 27.77
US$ 22.14
US$ 28.96
US$ 22.21
US$ 28.38
US$ 29.91
